Search

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

25.32 -0.82

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25

Max

25.89

Pagrindiniai rodikliai

By Trading Economics

Pajamos

191K

-51M

Pardavimai

6.7M

106M

Pelnas, tenkantis vienai akcijai

-0.46

Pelno marža

-47.808

Darbuotojai

1,784

EBITDA

-2.1M

-46M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+26.06% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

593M

2.6B

Ankstesnė atidarymo kaina

26.14

Ankstesnė uždarymo kaina

25.32

Naujienos nuotaikos

By Acuity

50%

50%

154 / 340 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-17 23:56; UTC

News
Social Media

Axon Enterprise shares are lower in after-market hours, following a report highlighting high valuations and recent military contracts from Bulgaria.

2026-08-17 23:56; UTC

News

Warner Bros Discovery shares are lower in after-market trading amid ongoing litigation over its merger with Paramount, which faces a $1.9 billion bond request.

2026-08-17 23:56; UTC

News

Allstate Corp shares are lower in after-market hours amid broader market weakness. Geopolitical concerns are affecting trading sentiment despite recent positive earnings highlights.

2026-08-17 23:56; UTC

News

Replimune Group Inc shares are lower in after-market hours amid negative sentiment from multiple class action lawsuits alleging securities fraud and misleading statements.

2026-08-17 23:46; UTC

Correlated Moves
News

ManpowerGroup Inc shares are lower in after-market hours amid concerns over declining sales and profitability, with operating margins reported at just 1.5%.

2026-08-17 23:46; UTC

News

Wix.com Ltd faces a securities class action lawsuit over alleged false statements about its AI offerings, contributing to shares trading roughly flat in after-hours activity.

2026-08-17 23:41; UTC

News

Coherus BioSciences announced a special dividend of contingent value rights, boosting shares in after-market trading following the company's strategic asset sale initiative.

2026-08-17 23:41; UTC

News
Social Media

XP Inc shares are lower in after-market hours after announcing a share cancellation and reporting mixed Q2 results, including adjusted net profit above estimates.

2026-08-17 23:36; UTC

News

Whirlpool Corp is identified as a sell by Yahoo Finance amid concerns over declining sales and profitability. Shares are trading lower in after-market hours.

2026-08-17 23:36; UTC

News

Enovix Corp shares are rising in after-market trading, rebounding from recent lows amid leadership changes and broader market declines for the Dow and S&P 500.

2026-08-17 23:31; UTC

News

Fred Stephan named President and CEO effective November 1, 2026.

2026-08-17 23:31; UTC

News

Zeta Global shares are lower in after-market hours, despite positive coverage highlighting strong performance and anticipated revenue growth of 25.1%.

2026-08-17 23:21; UTC

News

AT&T Inc. shares are higher in after-market trading following a successful €1.2 billion and $1.1 billion notes issuance to enhance liquidity and capital structure.

2026-08-17 23:16; UTC

News

Patterson-UTI Energy highlighted in Yahoo Finance cautionary analysis

2026-08-17 23:16; UTC

Social Media
News

Wendy's Co. shares are lower in after-market hours following the announcement of President Pete Suerken's resignation and a restructuring plan.

2026-08-17 23:16; UTC

News

Valero Energy shares are higher in after-market hours following analyst upgrades and price target increases amid rising crude oil prices linked to Middle East tensions.

2026-08-17 23:11; UTC

News

Nasdaq Inc plans to extend U.S. trading hours to nearly 23 hours daily starting December 6, 2026, pending regulatory approval. Shares are higher in after-market trading.

2026-08-17 23:06; UTC

News

DigitalOcean Holdings Inc. launched Managed AI Agents via Cloudways, contributing to shares trading higher after the market closed.

2026-08-17 23:01; UTC

News

Mitek Systems appoints Aaron Seyler as Chief Revenue Officer, effective August 17, 2026. Shares are trading higher in after-market hours.

2026-08-17 23:01; UTC

News

CACI awarded a contract worth up to $981 million with the U.S. Space Force, yet shares are trading lower in after-market hours.

2026-08-17 23:01; UTC

News

Targa Resources has secured long-term midstream agreements with ExxonMobil and plans to invest $5 billion in new projects, driving shares higher in after-market trading.

2026-08-17 23:01; UTC

News

Becton Dickinson appoints Gary Sorsher as executive vice president and chief quality officer, effective September 8. Shares are higher in after-market trading.

2026-08-17 23:01; UTC

News

Science Applications International Corp is under scrutiny after being flagged by Yahoo Finance. Shares are lower in after-hours trading following concerns over revenue projections.

2026-08-17 23:01; UTC

Correlated Moves
News
Social Media

iShares 20+ Year Treasury Bond ETF gains in after-market trading, reflecting market sentiment influenced by rising crude oil prices amid geopolitical tensions.

2026-08-17 23:01; UTC

News
Correlated Moves

BlackRock Inc shares declined in after-market trading, continuing a trend of lower daily closes amid geopolitical tensions and rising crude oil prices.

2026-08-17 22:56; UTC

Correlated Moves
News

Kulicke and Soffa Industries shares are lower in after-market trading following the announcement of Dr. Raj Talluri as the new CEO, effective September 2026.

2026-08-17 22:56; UTC

News

ComEd allocates over $170,000 to enhance public safety in 24 Illinois communities through its Powering Safe Communities Program. Exelon shares are higher in after-market trading.

2026-08-17 22:51; UTC

Social Media
News

Kura Oncology shares rose in after-market trading after CEO Troy Wilson's $1.11 million stock purchase and positive earnings report highlighting $9.1 million in revenue.

2026-08-17 20:07; UTC

News

Levi Strauss faces analyst skepticism over revenue performance and cash flow margins. The consensus price target is $28.27, implying a potential return of 26.2%.

2026-08-17 20:07; UTC

News
Correlated Moves

The iShares 7-10 Year Treasury Bond ETF is trading lower amid rising 10-year Treasury yields and geopolitical tensions affecting economic growth and inflation expectations.

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

26.06% į viršų

12 mėnesių prognozė

Vidutinis 32.65 USD  26.06%

Aukščiausias 45 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

3

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

154 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat